Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

MiR-218: a molecular switch and potential biomarker of susceptibility to stress.

Torres-Berrío A, Nouel D, Cuesta S, Parise EM, Restrepo-Lozano JM, Larochelle P, Nestler EJ, Flores C.

Mol Psychiatry. 2019 Apr 12. doi: 10.1038/s41380-019-0421-5. [Epub ahead of print]

2.

The impact of unrecorded readings on the precision and diagnostic performance of home blood pressure monitoring: a statistical study.

Rinfret F, Ouattara F, Cloutier L, Larochelle P, Ilinca M, Lamarre-Cliche M.

J Hum Hypertens. 2018 Mar;32(3):197-202. doi: 10.1038/s41371-018-0040-7. Epub 2018 Feb 21.

PMID:
29467411
3.

The Gap Between Manual and Automated Office Blood Pressure Measurements Results at a Hypertension Clinic.

Rinfret F, Cloutier L, L'Archevêque H, Gauthier M, Laskine M, Larochelle P, Ilinca M, Birnbaum L, Ng Cheong N, Wistaff R, Van Nguyen P, Roederer G, Bertrand M, Lamarre-Cliche M.

Can J Cardiol. 2017 May;33(5):653-657. doi: 10.1016/j.cjca.2017.01.021. Epub 2017 Feb 2.

PMID:
28449835
4.

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force.

Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066. Epub 2016 Mar 10.

PMID:
27118291
5.

Unreliability of home blood pressure measurement and the effect of a patient-oriented intervention.

Milot JP, Birnbaum L, Larochelle P, Wistaff R, Laskine M, Van Nguyen P, Lamarre-Cliche M.

Can J Cardiol. 2015 May;31(5):658-63. doi: 10.1016/j.cjca.2015.03.006. Epub 2015 Mar 11.

PMID:
25936491
6.

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS.

Can J Cardiol. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. Review.

PMID:
25936483
7.

Treatment of hypertension.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Gilbert RE, Rabi D, LaRochelle P, Leiter LA, Jones C, Ogilvie R, Tobe S, Khan N, Poirier L, Woo V.

Can J Diabetes. 2013 Apr;37 Suppl 1:S117-8. doi: 10.1016/j.jcjd.2013.01.033. Epub 2013 Mar 26. No abstract available.

PMID:
24070930
8.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer M, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M, Reid DJ, Tobe SW, Padwal RS, Poirier L; Canadian Hypertension Education Program.

Can J Cardiol. 2014 May;30(5):485-501. doi: 10.1016/j.cjca.2014.02.002. Epub 2014 Feb 22. Review.

9.

β-Blockers in hypertension: studies and meta-analyses over the years.

Larochelle P, Tobe SW, Lacourcière Y.

Can J Cardiol. 2014 May;30(5 Suppl):S16-22. doi: 10.1016/j.cjca.2014.02.012. Epub 2014 Feb 25. Review.

10.

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS; Canadian Hypertension Education Program.

Can J Cardiol. 2013 May;29(5):528-42. doi: 10.1016/j.cjca.2013.01.005. Epub 2013 Mar 29.

PMID:
23541660
11.

High blood pressure selected as the theme for World Health Day, April 7, 2013: cup half full or half empty?

Campbell NR, Feldman RD, Kaczorowski J, Larochelle P.

Can J Cardiol. 2013 Apr;29(4):415-7. doi: 10.1016/j.cjca.2013.01.014. Epub 2013 Feb 28. No abstract available.

PMID:
23454039
12.

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.

Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G.

Curr Oncol. 2012 Aug;19(4):202-8. doi: 10.3747/co.19.972.

13.

Hypertension revisited.

Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris S.

Can Fam Physician. 2012 Jun;58(6):634-6. No abstract available. Erratum in: Can Fam Physician. 2012 Aug;58(8):830.

14.

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NR, Reid D, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2012 May;28(3):270-87. doi: 10.1016/j.cjca.2012.02.018. Review.

PMID:
22595447
15.

Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease.

Goyer L, Dufour R, Janelle C, Blais C, L'Abbé C, Raymond E, de Champlain J, Larochelle P.

J Behav Med. 2013 Apr;36(2):212-24. doi: 10.1007/s10865-012-9407-3. Epub 2012 Mar 9.

PMID:
22402823
16.

Hypertension in people with type 2 diabetes: Update on pharmacologic management.

Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris SB.

Can Fam Physician. 2011 Sep;57(9):997-1002, e347-53. Review. English, French. Erratum in: Can Fam Physician. 2011 Nov;57(11):1255.

17.

[Seroprevalence of leptospirosis in Puente Piedra, Lima, in 2006].

Platts-Mills JA, LaRochelle P, Campos K, Vinetz JM, Gotuzzo E, Ricaldi JN.

Rev Peru Med Exp Salud Publica. 2011 Jun;28(2):273-6. Spanish.

18.

Comparative assessment of four blood pressure measurement methods in hypertensives.

Lamarre-Cliché M, Cheong NN, Larochelle P.

Can J Cardiol. 2011 Jul-Aug;27(4):455-60. doi: 10.1016/j.cjca.2011.05.001. English, French.

PMID:
21801977
19.

The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Campbell TS, Lindsay MP, Herman RJ, Larochelle P, Feldman RD, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2011 Jul-Aug;27(4):415-433.e1-2. doi: 10.1016/j.cjca.2011.03.015. English, French.

PMID:
21801975
20.

The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2010 May;26(5):249-58. Review.

21.

Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial.

Tamblyn R, Reidel K, Huang A, Taylor L, Winslade N, Bartlett G, Grad R, Jacques A, Dawes M, Larochelle P, Pinsonneault A.

Med Decis Making. 2010 Mar-Apr;30(2):176-88. doi: 10.1177/0272989X09342752. Epub 2009 Aug 12.

PMID:
19675319
22.

Post-PharmD industry fellowship opportunities and proposed guidelines for uniformity.

Larochelle PA, Giang DK, Silva MA, Kcomt M, Malloy MJ, Kay S, Ku MT.

Am J Pharm Educ. 2009 Feb 19;73(1):20.

23.

Hypertension in diabetes: a call to action.

Campbell NR, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, Morris D, Tsuyuki R.

Can J Cardiol. 2009 May;25(5):299-302. Review.

24.

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, DeChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program.

Can J Cardiol. 2009 May;25(5):287-98. Review.

25.
26.

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.

Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.

Blood Press. 2008;17(3):170-7. doi: 10.1080/08037050802169644.

PMID:
18608200
27.

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, Padwal R, Leiter LA, Mahon JL, Hill MD, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, dechamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Tobe S, Lewanczuk RZ; Canadian Hypertension Education Program.

Can J Cardiol. 2008 Jun;24(6):465-75. Review.

28.

Antihydrogen production within a Penning-Ioffe trap.

Gabrielse G, Larochelle P, Le Sage D, Levitt B, Kolthammer WS, McConnell R, Richerme P, Wrubel J, Speck A, George MC, Grzonka D, Oelert W, Sefzick T, Zhang Z, Carew A, Comeau D, Hessels EA, Storry CH, Weel M, Walz J; ATRAP Collaboration.

Phys Rev Lett. 2008 Mar 21;100(11):113001. Epub 2008 Mar 18.

PMID:
18517780
29.

Attenuation of autonomic nervous system functions in hypertensive patients at rest and during orthostatic stimulation.

Karas M, Larochelle P, LeBlanc RA, Dubé B, Nadeau R, Champlain Jd.

J Clin Hypertens (Greenwich). 2008 Feb;10(2):97-104.

30.

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Touyz RM, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2007 May 15;23(7):539-50.

31.

Antiproton confinement in a Penning-Ioffe trap for antihydrogen.

Gabrielse G, Larochelle P, Le Sage D, Levitt B, Kolthammer WS, Kuljanishvili I, McConnell R, Wrubel J, Esser FM, Glückler H, Grzonka D, Hansen G, Martin S, Oelert W, Schillings J, Schmitt M, Sefzick T, Soltner H, Zhang Z, Comeau D, George MC, Hessels EA, Storry CH, Weel M, Speck A, Nillius F, Walz J, Hänsch TW.

Phys Rev Lett. 2007 Mar 16;98(11):113002. Epub 2007 Mar 14.

PMID:
17501048
32.

Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients.

de Champlain J, Karas M, Assouline L, Nadeau R, LeBlanc AR, Dubé B, Larochelle P.

J Clin Hypertens (Greenwich). 2007 Mar;9(3):168-78.

33.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A; VALUE Trial Investigators.

J Hypertens. 2006 Jul;24(7):1405-12.

PMID:
16794491
34.

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.

Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM; Canadian Hypertension Education Program.

Can J Cardiol. 2006 May 15;22(7):583-93.

35.

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.

Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD; Canadian Hypertension Education Program.

Can J Cardiol. 2005 Jun;21(8):657-72.

PMID:
16003449
36.

Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.

Karas M, Lacourcière Y, LeBlanc AR, Nadeau R, Dubé B, Florescu M, Lamarre-Cliche M, Poirier L, Larochelle P, de Champlain J.

J Hypertens. 2005 Jun;23(6):1251-60.

PMID:
15894902
37.

Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.

Lamarre-Cliche M, de Champlain J, Lacourcière Y, Poirier L, Karas M, Larochelle P.

Am J Hypertens. 2005 Jan;18(1):56-64.

PMID:
15691618
38.

A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.

Poirier L, de Champlain J, Larochelle P, Lamarre-Cliche M, Lacourcière Y.

Blood Press Monit. 2004 Oct;9(5):231-6.

PMID:
15472494
39.

Does QTc interval predict the response to beta-blockers and calcium channel blockers in hypertensives?

Lamarre-Cliche M, Lacourcière Y, de Champlain J, Poirier L, Larochelle P.

Heart Dis. 2003 Jul-Aug;5(4):244-52.

PMID:
12877758
40.

Circadian variation in blood pressure: dipper or nondipper.

Larochelle P.

J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4 Suppl 1):3-8. Review.

41.

The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy.

McAlister FA, Zarnke KB, Campbell NR, Feldman RD, Levine M, Mahon J, Grover SA, Lewanczuk R, Leenen F, Tobe S, Lebel M, Stone J, Schiffrin EL, Rabkin SW, Ogilvie RI, Larochelle P, Jones C, Honos G, Fodor G, Burgess E, Hamet P, Herman R, Irvine J, Culleton B, Wright JM; Canadian Hypertension Recommendations Working Group.

Can J Cardiol. 2002 Jun;18(6):625-41.

PMID:
12107420
42.

Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.

Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, Black HR, Plouin PF, Levy D, Mancia G, Larochelle P, Kolloch RE, Alderman M, Ruilope LM, Dahlöf B, Flack JM, Wolf R; OPERA Study Group. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events.

Am J Hypertens. 2002 Feb;15(2 Pt 1):193-8.

PMID:
11863257
43.

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H.

J Hypertens. 2001 Jun;19(6):1149-59.

PMID:
11403365
44.

Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, McLeod P, Huang A, Larochelle P, Mallet L.

JAMA. 2001 Jan 24-31;285(4):421-9.

PMID:
11242426
45.

[Calcium channel blocking agents and albuminuria in diabetic and hypertensive patients. A pilot study].

Lamarre-Cliche M, Lambert R, Van Nguyen P, Cusson J, Wistaff R, Larochelle P.

Arch Mal Coeur Vaiss. 2000 Aug;93(8):919-24. French.

PMID:
10989730
46.

First-line antihypertensive therapy. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Feldman RD, Campbell N, Larochelle P.

Lancet. 2000 Aug 5;356(9228):509. No abstract available.

PMID:
10981916
47.

Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians.

Pausova Z, Deslauriers B, Gaudet D, Tremblay J, Kotchen TA, Larochelle P, Cowley AW, Hamet P.

Hypertension. 2000 Jul;36(1):14-9.

PMID:
10904006
48.

Sibling resemblance of erythrocyte ion transporters in French-Canadian sibling-pairs affected with essential hypertension.

Orlov SN, Pausova Z, Gossard F, Gaudet D, Tremblay J, Kotchen T, Cowley A, Larochelle P, Hamet P.

J Hypertens. 1999 Dec;17(12 Pt 2):1859-65.

PMID:
10703881
49.
50.

1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, Floras JS, Haynes RB, Honos G, Leenen FH, Leiter LA, Logan AG, Myers MG, Spence JD, Zarnke KB.

CMAJ. 1999;161 Suppl 12:S1-17.

Supplemental Content

Loading ...
Support Center